RxDoctor Payments DataLook up a doctor →

Paul Gurbel, MD

Cardiovascular Disease · Baltimore, MDNPI 1003888520

Payments from drug & device makers

$2,611,088in general payments, 2019–2025

Across 591 payments — averaging $4418.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haemonetics Corporation$682K
  • Novartis$582K
  • Eli Lilly$455K
  • Accriva Diagnostics Inc.$349K
  • Amgen$188K
  • Merck$151K
  • plus $204K from 44 others
$29,169in research payments, 2019–2025

Across 7 payments — averaging $4167.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$19K
  • Accriva Diagnostics Inc.$10K

What the payments were for

  • Consulting fees$12,36042%
  • Speaking & faculty fees$5,64019%
  • Travel & lodging$6702%
  • Food & beverage$10,74837%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,611,088 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$254,713
Medicare patients
543
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$169,408
Repatha SureclickEvolocumab84$100,983
EntrestoSacubitril/Valsartan44$70,169
XareltoRivaroxaban36$46,359
BrilintaTicagrelor41$44,625
Praluent PenAlirocumab35$21,107
VascepaIcosapent Ethyl25$16,430
Ezetimibe185$9,682
Atorvastatin Calcium409$7,844
Rosuvastatin Calcium269$6,435
Metoprolol Succinate256$5,167
Icosapent Ethyl11$5,040
Amiodarone Hcl50$2,595
Irbesartan63$1,850
ClopidogrelClopidogrel Bisulfate70$1,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$427$169,408119 claims
NovartisEntresto$581,870$70,16944 claims
Johnson & JohnsonXarelto$4,019$46,35936 claims
AstraZenecaBrilinta$428$44,62541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →